• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Bone Scintigraphy in Staging of Newly Diagnosed Prostate Cancer in Regard of Different Risk Groups.不同风险组新诊断前列腺癌分期中的骨闪烁显像
Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):149-152. doi: 10.22038/AOJNMB.2019.35768.1242.
2
Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.确定新诊断的中危局限性前列腺癌患者进行同位素骨扫描的途径和指征——来自一个大型同期队列的结果
BJU Int. 2017 Nov;120(5B):E59-E63. doi: 10.1111/bju.13850. Epub 2017 Apr 19.
3
A Bone Scan Is Valuable for Primary Staging of Newly Diagnosed Prostate Cancer in a Low-Resource Setting (Nigeria).在资源匮乏地区(尼日利亚),骨扫描对新诊断前列腺癌的初始分期很有价值。
Nucl Med Mol Imaging. 2022 Apr;56(2):96-101. doi: 10.1007/s13139-021-00735-1. Epub 2022 Jan 28.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients.将Gleason分级作为新诊断前列腺癌患者核素骨扫描检查的首要标准的应用情况。
ScientificWorldJournal. 2009 Oct 2;9:1040-5. doi: 10.1100/tsw.2009.113.
6
Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.所有新诊断为前列腺癌的患者都需要进行分期放射性核素骨扫描吗?一项回顾性研究。
Int Braz J Urol. 2010 Nov-Dec;36(6):685-91; discussion 691-2. doi: 10.1590/s1677-55382010000600006.
7
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.初诊前列腺癌患者何时行骨扫描:当前可用指南的外部验证及新型风险分层工具的提出。
Eur Urol. 2010 Apr;57(4):551-8. doi: 10.1016/j.eururo.2009.12.023. Epub 2009 Dec 18.
8
A study on staging bone scans in newly diagnosed prostate cancer.一项关于新诊断前列腺癌骨扫描分期的研究。
Urol Int. 2006;76(3):209-12. doi: 10.1159/000091620.
9
Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.血清前列腺特异性抗原作为新诊断前列腺癌影像学分期研究的预测指标。
Cancer Invest. 1995;13(1):31-5. doi: 10.3109/07357909509024892.
10
[Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].[前列腺特异性抗原和Gleason评分对前列腺癌患者放射性核素骨显像结果的预测价值]
Beijing Da Xue Xue Bao Yi Xue Ban. 2012 Aug 18;44(4):528-34.

引用本文的文献

1
Bone scintigraphy based on deep learning model and modified growth optimizer.基于深度学习模型和改进型增长优化器的骨闪烁显像
Sci Rep. 2024 Oct 27;14(1):25627. doi: 10.1038/s41598-024-73991-8.
2
Machine Learning and Radiomics of Bone Scintigraphy: Their Role in Predicting Recurrence of Localized or Locally Advanced Prostate Cancer.骨闪烁扫描的机器学习与影像组学:它们在预测局限性或局部进展性前列腺癌复发中的作用。
Diagnostics (Basel). 2023 Nov 3;13(21):3380. doi: 10.3390/diagnostics13213380.
3
Diagnostic and cost-effectiveness of axial skeleton MRI in staging high-risk prostate cancer.轴向骨骼磁共振成像在高危前列腺癌分期中的诊断价值及成本效益分析
BJUI Compass. 2023 Jan 31;4(3):346-351. doi: 10.1002/bco2.210. eCollection 2023 May.
4
A Bone Scan Is Valuable for Primary Staging of Newly Diagnosed Prostate Cancer in a Low-Resource Setting (Nigeria).在资源匮乏地区(尼日利亚),骨扫描对新诊断前列腺癌的初始分期很有价值。
Nucl Med Mol Imaging. 2022 Apr;56(2):96-101. doi: 10.1007/s13139-021-00735-1. Epub 2022 Jan 28.

本文引用的文献

1
Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts.前列腺癌和乳腺癌骨闪烁扫描的合理使用标准:总结与摘录
J Nucl Med. 2017 Apr;58(4):14N-17N.
2
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.用于前列腺癌放射性核素成像与治疗的PSMA配体:临床现状
Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015.
3
Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.来自农村和郊区患者的前列腺癌——前列腺特异性抗原(PSA)值、 Gleason评分以及骨扫描中转移灶的存在情况
Ann Agric Environ Med. 2014;21(4):888-92. doi: 10.5604/12321966.1129953.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.连续确诊前列腺癌患者的骨闪烁扫描前瞻性多中心研究。
Clin Nucl Med. 2014 Jan;39(1):26-31. doi: 10.1097/RLU.0000000000000291.
6
Retrospective study of predictors of bone metastasis in prostate cancer cases.前列腺癌病例骨转移预测因素的回顾性研究。
Asian Pac J Cancer Prev. 2013;14(5):3289-92. doi: 10.7314/apjcp.2013.14.5.3289.
7
Choline PET/CT for imaging prostate cancer: an update.胆碱 PET/CT 用于前列腺癌成像:更新。
Ann Nucl Med. 2013 Aug;27(7):581-91. doi: 10.1007/s12149-013-0731-7. Epub 2013 Apr 30.
8
PET imaging in prostate cancer: focus on prostate-specific membrane antigen.前列腺癌的 PET 成像:关注前列腺特异性膜抗原。
Curr Top Med Chem. 2013;13(8):951-62. doi: 10.2174/1568026611313080008.
9
Imaging of bone metastases in prostate cancer: an update.前列腺癌骨转移的影像学:最新进展
Q J Nucl Med Mol Imaging. 2012 Oct;56(5):447-58.
10
Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?前列腺癌骨转移的现代检测:骨扫描时代是否已终结?
Adv Urol. 2012;2012:893193. doi: 10.1155/2012/893193. Epub 2011 Oct 16.

不同风险组新诊断前列腺癌分期中的骨闪烁显像

Bone Scintigraphy in Staging of Newly Diagnosed Prostate Cancer in Regard of Different Risk Groups.

作者信息

Sevcenco Sabina, Grubmüller Bernhard, Sonneck-Koenne Charlotte, Ahmadi Yasaman, Knoll Peter, Floth Andreas, Pokieser Wolfgang, Zandieh Shahin, Christoph Klingler Hans, Shariat Sharokh, Mirzaei Siroos

机构信息

Department of Urology, SMZ Ost, Donauspital, Vienna, Austria.

Department of Urology, University of Vienna, Austria.

出版信息

Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):149-152. doi: 10.22038/AOJNMB.2019.35768.1242.

DOI:10.22038/AOJNMB.2019.35768.1242
PMID:31380454
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6661314/
Abstract

OBJECTIVES

Prostate cancer (PC) is the most common cancer in men over 50 years of age. Bone scintigraphy is still performed in many institutions at the time of primary diagnosis. We aimed to evaluate the role of bone scan in the primary staging of PC in regard of different risk groups.

METHODS

A retrospective analysis of bone scans in 296 patients (mean age 64±6 y) acquired at the time of primary diagnosis was performed in our institution. The median prostate specific antigen (PSA) was 6.73 ng/ml, all patients had a Gleason score of >5.

RESULTS

Only 11/296 patients had a positive bone scan, 1 being in the intermediate risk group, 10 in the high-risk group and none in the low-risk group according to D'Amico classification.

CONCLUSION

Our results support the few published studies that less than 10% of patients with newly diagnosed PC by biopsy would develop bone metastasis, all in the intermediate or high-risk groups. Therefore, a staging by bone scan can only be recommended in patients with intermediate or high-risk, or symptomatic patients only.

摘要

目的

前列腺癌(PC)是50岁以上男性中最常见的癌症。在许多机构,初次诊断时仍会进行骨闪烁扫描。我们旨在评估骨扫描在不同风险组PC初次分期中的作用。

方法

我们机构对296例初次诊断时进行骨扫描的患者(平均年龄64±6岁)进行了回顾性分析。前列腺特异性抗原(PSA)中位数为6.73 ng/ml,所有患者的Gleason评分均>5。

结果

根据达米科分类,296例患者中只有11例骨扫描呈阳性,其中1例属于中危组,10例属于高危组,低危组无阳性病例。

结论

我们的结果支持了少数已发表的研究,即经活检新诊断的PC患者中,不到10%会发生骨转移,且均在中危或高危组。因此,仅建议对中危或高危患者或有症状的患者进行骨扫描分期。